Medicare drug price negotiation 2026 is here, and the first negotiated prices—called Maximum Fair Prices—took effect on January 1, 2026. If you take medications for diabetes, cardiovascular disease, or blood thinners, these changes could lower what you pay. Below, we explain the new 2026 prices, show how to confirm them in Medicare Plan Finder, and highlight why this matters for many North Carolina seniors.
What changed on January 1, 2026, under the Medicare Drug Price Negotiation Program?
On January 1, 2026, Medicare began using negotiated Maximum Fair Prices (MFPs) for the first 10 selected Part D drugs, following the Inflation Reduction Act. The law allows CMS to negotiate prices with participating drug companies for certain high-spending, single-source brand-name drugs covered under Medicare Part D. CMS reports that if these 2026 prices had applied in 2023, Medicare would have saved about $6 billion, or 22% lower net Medicare spending, with beneficiaries projected to save $1.5 billion in 2026. These negotiated prices apply to all Medicare prescription drug plans and Medicare Advantage plans with drug coverage.
The Centers for Medicare & Medicaid Services (CMS) published each selected drug’s negotiated 2026 MFP for a 30‑day supply, alongside 2023 list prices and usage. The negotiation process considered clinical benefit, unmet medical need, comparative effectiveness, and information submitted by drug manufacturers, among other factors under CMS guidance. Here are the 10 drugs and their 2026 MFPs for a 30‑day supply:
- Januvia (sitagliptin): $113.00 MFP; compared with $527 list (−79%). Used by ~843,000 Part D enrollees in 2023.
- Fiasp/NovoLog insulin aspart products: $119.00 MFP; $495 list (−76%). ~785,000 users in 2023.
- Farxiga (dapagliflozin): $178.50 MFP; $556 list (−68%). ~994,000 users in 2023.
- Enbrel (etanercept): $2,355.00 MFP; $7,106 list (−67%). ~48,000 users in 2023.
- Jardiance (empagliflozin): $197.00 MFP; compared with a 2023 list in CMS’s table; ~1.88 million users in 2023.
- Stelara (ustekinumab): $4,695.00 MFP; $13,836 list (−66%). ~23,000 users in 2023.
- Xarelto (rivaroxaban): $197.00 MFP; $517 list (−62%). ~1.32 million users in 2023.
- Eliquis (apixaban): $231.00 MFP; $521 list (−56%). ~3.93 million users in 2023.
- Entresto (sacubitril/valsartan): $295.00 MFP; $628 list (−53%). ~664,000 users in 2023.
- Imbruvica (ibrutinib): $9,319.00 MFP; $14,934 list (−38%). ~17,000 users in 2023.
CMS also maintains a public file of selected drugs and negotiated prices, including unit pricing, that plans and pharmacies use to administer benefits in 2026. For each drug selected, the Maximum Fair Price is not simply a public benchmark; it is part of how the Medicare program now works with plans, pharmacies, and manufacturers to effectuate lower negotiated amounts. For beneficiaries, the big takeaway is that plans must include these selected drugs on their formularies while MFPs are in effect.

How do I verify my 2026 drug prices in Medicare Plan Finder step by step?
You can confirm 2026 pricing for your medications in the official Medicare Plan Finder. The tool estimates monthly and yearly costs for your drugs under each plan in your ZIP code, including drugs covered under Medicare Part D and Medicare Advantage plans with drug coverage. Follow these steps to see your 2026 costs:
- Go to the Medicare plan comparison tool and enter your ZIP code. Choose either “Medicare drug plan (Part D)” or a Medicare Advantage plan with drug coverage.
- Add each prescription drug, dose, and frequency. Include your preferred pharmacies, such as a Charlotte-area preferred chain or local pharmacy.
- Review the plan results sorted by total estimated annual cost. Click “View drugs & their costs” inside a plan to see pharmacy-specific copays or coinsurance for each fill in 2026.
- Check the drug’s tier, any prior authorization, step therapy, or quantity limits that can affect your cost or access in 2026.
- Compare prices at preferred vs. standard pharmacies and look at mail‑order options—these can materially change what you pay in 2026.
Important: Plan Finder shows your plan-based cost sharing; it doesn’t label “MFP” directly. However, your coinsurance is applied to your plan’s negotiated rate, which incorporates the 2026 Maximum Fair Price where applicable. CMS confirms that MFPs took effect January 1, 2026 and that plans must cover selected drugs.
Two more 2026 cost protections to review while you compare:
- 2026 out-of-pocket cap: $2,100. In 2026, your total out-of-pocket spending for covered Part D drugs stops at $2,100 (up from $2,000 in 2025, adjusted by law). After you hit this threshold, you won’t owe more cost sharing for covered Part D drugs for the rest of the year.
- Medicare Prescription Payment Plan. If your drug costs are lumpy, you can opt to spread 2026 out-of-pocket costs over the year in monthly bills; this doesn’t change the total you owe, but it can ease cash flow.
Which common North Carolina health needs make 2026 negotiated prices especially relevant?
Many North Carolina seniors manage diabetes or cardiovascular disease—conditions squarely impacted by the 10 selected drugs. Nationally, about 20.1% of adults age 65+ have diagnosed diabetes, which aligns with the large 2023 user counts for diabetes and heart therapies like Jardiance, Farxiga, and Entresto. In 2023, 1.88 million Medicare beneficiaries used Jardiance and 994,000 used Farxiga under Part D.
North Carolina also experiences a significant burden from heart disease. CDC reports an age‑adjusted heart disease death rate of 155.5 per 100,000 in North Carolina, underscoring the importance of access to affordable cardiovascular medications. For blood thinners widely used across the state, 2023 Part D utilization included ~3.93 million users of Eliquis and ~1.32 million users of Xarelto nationally, both subject to 2026 MFPs.
For insulin users, 2026 brings further relief. Beginning in 2026, a one‑month supply of each covered insulin is capped at the lesser of $35, 25% of the MFP, or 25% of the plan’s negotiated price. That means insulin aspart products (Fiasp/NovoLog) have both MFP‑based pricing and the insulin cap applying at the counter.

What are “Maximum Fair Prices,” and do I ever “pay the MFP” at the pharmacy?
The negotiated 2026 MFP is the ceiling price that Medicare plans and dispensing entities may pay for a selected drug. Beneficiaries typically pay their plan’s copay or coinsurance based on the plan’s negotiated rate for that fill; the MFP operates behind the scenes to lower plan‑paid amounts and, indirectly, many patient coinsurance amounts. Plans must place selected drugs on their 2026 formularies while MFPs are in effect.
In practical terms, Medicare does not ask you to negotiate drug prices at the pharmacy counter. CMS and participating drug companies negotiate prices through the federal program, while your plan applies its formulary, network pharmacy pricing, and cost-sharing rules when your claim is processed.
How do the 2026 negotiated prices interact with Medicare Advantage HMO/PPO plans vs. stand‑alone Part D?
Whether you enroll in a Medicare Advantage HMO/PPO with drug coverage or a stand‑alone Part D plan, the 2026 negotiated prices apply to the selected drugs. Your out‑of‑pocket costs still depend on each plan’s formulary tiering, preferred pharmacy network, and utilization rules—details you can compare in Plan Finder before you enroll for 2026 coverage.

This is why two plans can cover the same drugs but estimate different costs for the same person. A Medicare Part D plan may use different preferred pharmacies, prior authorization rules, or tier structures than another plan, even when the negotiated Maximum Fair Price applies in the background.
What’s next in 2027 and 2028 for Medicare drug price negotiations?
CMS selected 15 additional Part D drugs for negotiation for 2027; negotiations occurred in 2025, and the resulting MFPs take effect on January 1, 2027. The list includes widely used drugs like GLP‑1s (Ozempic, Rybelsus, Wegovy), among others. Looking ahead, the 2028 cycle includes the first Part B drugs, with negotiations in 2026 for prices effective January 1, 2028.
The schedule matters because CMS will continue to select additional drugs in future cycles, meaning the Medicare program will negotiate prices for more high-spending medications over time. For North Carolina retirees and caregivers, the practical takeaway is to review plan choices annually because formulary coverage, pharmacy networks, and negotiated drug prices can change from one plan year to the next.
How to make your personal 2026 plan comparison stronger (practical tips from local advisors)
- Run your medications through Plan Finder twice—once with your current pharmacy and again with a preferred low‑cost pharmacy—because pharmacy choice can change 2026 costs by hundreds of dollars.
- Open a plan’s “View drugs & their costs” section and look for tier, prior authorization, step therapy, and quantity limits that may apply in 2026.
- Confirm whether all your drugs are covered, not just whether your most expensive medication appears on the formulary, because non-selected prescriptions can still drive total annual cost.
- Factor in the $2,100 out‑of‑pocket cap for 2026 and consider enrolling in the Medicare Prescription Payment Plan to spread payments over the year.
- If a pharmacy can’t process the lower cost, ask the plan or pharmacy to confirm the claim is adjudicating with the correct 2026 data. Pharmacies and manufacturers use the new Medicare Transaction Facilitator (MTF) to effectuate MFP claims beginning in 2026.
Frequently asked questions about Medicare drug price negotiations in 2026
Do these negotiated prices guarantee my copay goes down in 2026?
Not always, but they often help. Your cost depends on plan design, tiering, and pharmacy network. Still, CMS projected $1.5 billion in 2026 beneficiary savings from the first 10 negotiated drugs, and you’re also protected by the $2,100 2026 out‑of‑pocket cap.
Where can I see the official 2026 Maximum Fair Prices?
CMS published the 2026 MFPs for all 10 selected Part D drugs, including each 30‑day MFP and a comparison to prior list prices. Plans must include these selected drugs on their formularies while MFPs are in effect.
How do I confirm my personal 2026 costs?
Use Medicare Plan Finder to enter your drugs, doses, and pharmacies, then review 2026 plan results and drug‑level pricing. Look for tiering and restrictions that may affect your access or cost under each plan.
Does the insulin $35 rule still apply in 2026?
Yes—with an update. For 2026, each covered insulin’s cost at the counter is the lesser of $35, 25% of the MFP, or 25% of the plan’s negotiated price.
Are 2027 negotiated prices already set?
CMS selected 15 additional drugs for 2027, conducted negotiations in 2025, and will implement the resulting MFPs on January 1, 2027. CMS has also started preparations for 2028, when some Part B drugs join the program.
Will these negotiated prices affect non‑Medicare insurance?
The Medicare Drug Price Negotiation Program applies to Medicare. While market dynamics can influence broader pricing, MFPs are specific to Medicare coverage and the Medicare program’s benefit design.
Why work with a local, independent advisor now that 2026 prices are live?
With 2026 negotiated prices in place and the 2027 cycle on deck, the smartest move is to re‑shop your coverage with your actual medications and pharmacies. Our Charlotte-based team understands North Carolina formularies and pharmacy networks, and we routinely help seniors compare Medicare Advantage HMO/PPO and stand‑alone Part D options using real‑world drug lists, preferred pharmacies, and utilization management rules. We also help caregivers navigate Extra Help, insulin caps, and the Medicare Prescription Payment Plan.
Talk with Safeguard Benefit Services
If you take a selected drug like Eliquis, Xarelto, Januvia, or Entresto—or you manage diabetes or heart disease—there is money on the table in 2026. We’ll help you verify your 2026 plan‑level prices in Medicare Plan Finder, review pharmacy options around Charlotte, and compare Medicare Advantage vs. Part D so you can keep your doctors and your budget on track. Contact Safeguard Benefit Services for a no‑pressure, personalized review: /.
References and data sources (selected)

- Centers for Medicare & Medicaid Services. “Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026” (Fact Sheet/PDF; includes 30‑day 2026 MFPs, list prices, and 2023 utilization). August 2024; accessed July 16, 2026.
- CMS. “Selected Drugs and Negotiated Prices.” Data file and updates for 2026 MFPs. Accessed July 16, 2026.
- Medicare.gov. “How do drug plans work?” and Plan Finder resources; notes that initial negotiated prices took effect January 1, 2026. Accessed July 16, 2026.
- CMS. “Final CY 2026 Part D Redesign Program Instructions” and Medicare.gov Part D costs page—2026 out‑of‑pocket threshold of $2,100. Accessed July 16, 2026.
- CMS. 2026 Advance Notice Fact Sheet—insulin cost sharing rule for 2026 (lesser of $35, 25% MFP, or 25% negotiated price). Accessed July 16, 2026.
- HHS/ASPE. “Medicare Prices Negotiated for 2026 Compared to List and U.S. Market Prices.” Accessed July 16, 2026.
- CMS. “HHS Announces 15 Additional Drugs Selected for Medicare Drug Price Negotiations…” (2027 cycle). January 17, 2025.
- CDC. Stats of the States—Heart Disease Mortality (North Carolina). Accessed July 16, 2026.
About Safeguard Benefit Services
Safeguard Benefit Services is an independent insurance agency serving North Carolina. We specialize in Medicare, including Medicare Advantage (Part C), stand‑alone Part D, Medigap, and Special Needs Plans. We offer personalized, compliant plan comparisons that help North Carolina seniors and caregivers make confident 2026 coverage decisions.
Professional disclaimer
This material is for educational purposes only and is not legal, medical, tax, or financial advice. Medicare rules, drug lists, and prices may change; verify details with Medicare.gov, your plan, or CMS resources. Safeguard Benefit Services is not connected with or endorsed by the U.S. government or the federal Medicare program. We do not offer every plan available in your area. Any information we provide is limited to the plans we do offer in your area. For a full list of options, visit Medicare.gov or call 1‑800‑MEDICARE.
Sources
- cms.gov — Medicare Drug Price Negotiation Program Negotiated Prices Initial Price Applicability Year 2026
- cms.gov — Fact Sheet Negotiated Prices Initial Price Applicability Year 2026
- cms.gov — Selected Drugs Negotiated Prices
- medicare.gov — Plan Compare
- medicare.gov — Helpful Tools
- medicare.gov — How Drug Plans Work
- cms.gov — Final Cy 2026 Part D Redesign Program Instructions
- medicare.gov — Prescription Payment Plan
- blogs.cdc.gov — Nchs
- cdc.gov — Heart Disease
- cms.gov — 2026 Medicare Advantage Part D Advance Notice Fact Sheet
- cms.gov — Hhs Announces 15 Additional Drugs Selected Medicare Drug Price Negotiations Continued Effort Lower
- cms.gov — Pharmacy Dispensing Entity Resources
- aspe.hhs.gov — Medicare Prices Negotiated 2026




Get Connected